1. Home
  2. CNTB vs BOLD Comparison

CNTB vs BOLD Comparison

Compare CNTB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTB
  • BOLD
  • Stock Information
  • Founded
  • CNTB 2012
  • BOLD 2018
  • Country
  • CNTB United States
  • BOLD United States
  • Employees
  • CNTB N/A
  • BOLD N/A
  • Industry
  • CNTB Biotechnology: Pharmaceutical Preparations
  • BOLD
  • Sector
  • CNTB Health Care
  • BOLD
  • Exchange
  • CNTB Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • CNTB 68.5M
  • BOLD 81.0M
  • IPO Year
  • CNTB 2021
  • BOLD 2024
  • Fundamental
  • Price
  • CNTB $1.17
  • BOLD $2.95
  • Analyst Decision
  • CNTB Strong Buy
  • BOLD Strong Buy
  • Analyst Count
  • CNTB 1
  • BOLD 3
  • Target Price
  • CNTB $8.00
  • BOLD $23.00
  • AVG Volume (30 Days)
  • CNTB 24.6K
  • BOLD 57.8K
  • Earning Date
  • CNTB 09-05-2024
  • BOLD 11-11-2024
  • Dividend Yield
  • CNTB N/A
  • BOLD N/A
  • EPS Growth
  • CNTB N/A
  • BOLD N/A
  • EPS
  • CNTB N/A
  • BOLD N/A
  • Revenue
  • CNTB $24,116,000.00
  • BOLD N/A
  • Revenue This Year
  • CNTB N/A
  • BOLD N/A
  • Revenue Next Year
  • CNTB $63.90
  • BOLD N/A
  • P/E Ratio
  • CNTB N/A
  • BOLD N/A
  • Revenue Growth
  • CNTB N/A
  • BOLD N/A
  • 52 Week Low
  • CNTB $0.68
  • BOLD $2.82
  • 52 Week High
  • CNTB $2.84
  • BOLD $15.24
  • Technical
  • Relative Strength Index (RSI)
  • CNTB 44.02
  • BOLD N/A
  • Support Level
  • CNTB $1.18
  • BOLD N/A
  • Resistance Level
  • CNTB $1.26
  • BOLD N/A
  • Average True Range (ATR)
  • CNTB 0.07
  • BOLD 0.00
  • MACD
  • CNTB -0.01
  • BOLD 0.00
  • Stochastic Oscillator
  • CNTB 13.59
  • BOLD 0.00

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: